THAT Share Price Performance
UK£0.0063
0.00 (66.67%)
Price UK£0.0063
Share Pricen/a
Thalia Therapeutics Plc Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
THAT Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Thalia Therapeutics Plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.0013
- 100.00%
- -15,600.13%
- 0%
About THAT
- Founded
- 1979
- Employees
- 4
- CEO
- WebsiteView website
Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. Thalia Therapeutics Plc was formerly known as N4 Pharma Plc and changed its name to Thalia Therapeutics Plc in March 2026. Thalia Therapeutics Plc was incorporated in 1979 and is based in Chellaston, the United Kingdom.
